JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (10): 77-80,95.doi: 10.6040/j.issn.1671-7554.0.2014.360

Previous Articles     Next Articles

Expression and significance of GDF9 and BMP15 in follicular fluid of women with polycysticovary syndrome

HA Lingxia1,2, LI Xianghong1,2   

  1. 1. Center for Reproductive Medicine, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China;
    2. Key Laboratory of Reproduction and Genetics, Key Laboratory of Fertility Preservation and Maintenance, Ningxia Medical University, Ministry of Education in Ningxia, Yinchuan 750004, Ningxia, China
  • Received:2014-06-01 Revised:2014-09-12 Online:2014-10-10 Published:2014-10-10

PDF (PC)

338

Abstract: Objective To investigate the expression of growth differentiation factor9 (GDF9) and bone morphogenetic protein15 (BMP15) in follicular fluid of polycystic ovarian syndrome (PCOS) patients and the effects on the outcome of in vitro fertilization and embryo transfer (IVF-ET). Methods A total of 60 PCOS patients (PCOS group) and 60 women with normal ovarian function (control group) were collected. The general information, the numbers of oocytes, mature oocytes, fertilized oocytes, cleavage, high quality embryos, and the rate of clinical pregnancy were recorded. Western blotting was used to detect the expressions of GDF9 and BMP15 in the follicular fluid of all subjects. The PCOS group was further divided into pregnant and non-pregnant subgroups according to the presence of a gestational sac on ultrasound. The expressions of GDF9 and BMP15 were analyzed. Results ① The number of oocytes was 18.76±8.51 and 11.23±4.29 in the PCOS group and control group, with significant difference (P<0.05). The number ofmature eggs, fertilization rate, cleavage rate, good quality embryo and the clinical pregnancy rate between the two groups had no significant differences (P>0.05). ② The expressions of GDF9 and BMP15 were 0.85±0.27 and 1.29±0.48 in the PCOS group, and 1.33±0.24 and 1.94±0.57 in the control group, with significant difference (P<0.05). ③ The expressions of GDF9 and BMP15 were 1.01 ± 0.31 and 1.50 ± 0.41 in the pregnant subgroup, and 0.71±0.21 and 1.09±0.46 in the non-pregnant subgroup, with significant difference (P<0.05). Conclusion The expressions of GDF9 and BMP15 in follicular fluid in the PCOS group are lower than those of the control group, suggesting that the low expression may affect oocyte quality and embryo development potential. The expressions of GDF9 and BMP15 in follicular fluid of the pregnant subgroup are higher than those of the non-pregnant subgroup, suggesting that the high expression may be associated with a good pregnancy outcome.

Key words: Polycystic ovary syndrome, In vitro fertilization and embryo transfer, Growth differentiation factor 9, Bone morphogenetic protein 15

CLC Number: 

  • R711.6
[1] March W A, Moore V M, Willson K J, et al. The prevalence of polycystic ovary syndrome in acommunity sample assessed under contrasting diagnostic criteria[J]. Hum Reprod, 2010, 25(2):544-551.
[2] Gilchrist R B, Lane M, Thompson J G. Oocyte-secreted factors:regulators of cumulus cell function and oocyte quality[J]. Hum Reprod Update, 2008, 14(2):159-177.
[3] Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function[J]. Mol Reprod Dev, 2011, 78(1):9-21.
[4] Van Houten E L, Laven J S, Louwers Y V, et al. Bone morphogenetic proteins and the polycystic ovary syndrome[J]. J Ovarian Res, 2013, 6(1):32. doi:10.1186/1757-2215-6-32.
[5] Wei L N, Liang X Y. Growth Differentiation Factor 9, Bone Morphogenetic Protein 15 and Polycystic Ovary Syndrome[J]. J Int Reprod/Fam Plan, 2011, 30:251-254.
[6] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1):41-47.
[7] Okohue J E, Onuh S O, Ikimalo J I. Comparison of IVF/ICSI outcome in patients with polycystic ovarian syndrome or tubal factor infertility[J]. Niger J Clin Pract, 2013, 16(2):207-210.
[8] Dumesic D A, Abbott D H. Implications of polycystic ovary syndrome on oocyte development[J]. Semin Reprod Med, 2008, 11(1):53-61.
[9] Qiao J, Feng H L. Extra-and intra-ovarian factors in polycystic ovary syndrome:impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011, 17(1):17-33.
[10] Han A R, Kim H O, Cha S W, et al. Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome:a case control study[J]. Clin Exp Reprod Med, 2011, 38(2):103-108.
[11] Welt C K, Gudmundsson J A, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria:the impact of weight on phenotype and metabolic features[J]. J Clin Endocrinol Metab, 2006, 91 (12):4842-4848.
[12] Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function[J]. Mol Reprod Dev, 2011, 78(1):9-21.
[13] Paulini F, Melo E O. The role of oocyte-secreted factors GDF9 and BMP15 in follicular development and oogenesis[J]. Reprod Domest Anim, 2011, 46(2):354-361.
[14] Wei L N, Liang X Y, Fang C, et al. Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome[J]. Fertil Steril, 2011, 96(2):464-468.
[15] Zhao S Y, Qiao J, Chen Y J, et al. Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome[J]. Fertil Steril, 2010, 94(1):261-267.
[16] Wei L N, Li L L, Fang C, et al. Inhibitory effects of controlled ovarian stimulation on the expression of GDF9 and BMP15 in oocytes from women with PCOS[J]. J Assist Reprod Genet, 2013, 30(10):1313-1318.
[17] Yeo C X, Gilchrist R B, Lane M. Disruption of bidirectional oocyte-cumulus paracrine signaling during in vitro maturation reduces subsequent mouse oocyte developmental competence[J]. Biol Reprod, 2009, 80(5):1072-1080.
[18] Su J, Wang Y, Zhang L, et al. Oocyte-secreted factors in oocyte maturation media enhance subsequent development of bovine cloned embryos[J]. Mol Reprod Dev, 2014, 81(4):341-349.
[19] Wu Y T, Tang L, Cai J, et al. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development[J]. Hum Reprod, 2007, 22(6):1526-1531.
[20] Zhang Y M, Lin X N, Zhou F, et al. Influence of Bone Morphogenetic Protein(BMP)-15 on the IVF Outcomes of Endometriosis-A Clinical Trail and Experimental Research[J]. Journal of Reproduction & Contraception, 2012, 32(11):739-743.
[1] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60-66.
[2] ZHANG Suping, WANG Ze, ZHOU Yali, LI Jing, LU Xilan, BAI Hongwei, SHI Yuhua. Clinical effects of body mass index on ovulation induction treatment with letrozole among women with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 81-85.
[3] YANG Dongzi, MAI Zhuoyao. Features of ovarian reserve and outcomes of assisted reproductive technology in elder patients with PCOS [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 26-32.
[4] JIA Yueyue, LIU Hongbin, LI Jingbo, LI Jing, ZHANG Jiangtao, SUN Mei, SHI Yuhua. Expression of microRNA-200b in granulosa cells of PCOS patients and its significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 63-68.
[5] LI Jingbo, LIU Hongbin, JIA Yueyue, WANG Ze, SUN Mei, SHI Yuhua. Expression and clinical significance of microRNA-183 in polycystic ovary syndrome with insulin resistance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 69-74.
[6] ZHANG Lin, LI Jing, WANG Ze, ZHANG Jiangtao, MA Zengxiang, SHI Yuhua. Impact of thyroid-stimulating hormone on blood glucose and serum lipids in patients with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 80-84.
[7] HA Ling-xia1,2, SHI Yu-hua1, ZHAO Jun-li2, CHEN Zi-jiang1. A comparison of lipid metabolism in PCOS patients with different testosterone levels in Ningxia Hui Autonomous Region [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 88-91.
[8] YANG Liu, ZHANG Lei, LI Chun-hui, WAGN Zhi-ping. Association between microsatellite polymorphism of gene CYP11a and polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(10): 85-89.
[9] WANG Wei1, HUA Tian2, CAO Jin-feng1, CUI Na1, YANG Ai-min1, JIANG Lei1, HAO Gui-min1. Effect of letrozole on the ovulation stimulation among the patients with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 25-28.
[10] ZHENG Rong-hua, SHI Yu-hua, SHENG Yan, GAO Qin, GAO Xuan, CHEN Zi-Jiang . Changing Characteristics of peripheral white blood cell counts in patients with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 78-80.
[11] WANG Yue-heng1， XING Yi2， WANG Jiu-ling1， DAI Jun3， LI Shu-ling1. Changes and significances of serum visfatin and TNF-α in
patients with polycystic ovary syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 94-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd